陈丽昆

一、基本情况

职称：教授、主任医师、博士生导师

专家门诊时间：周二上午、周四上午及下午

专业特长：从事肿瘤内科治疗的临床工作及抗癌药物研究，特别擅长肺癌的内科治疗（化疗、靶向治疗、免疫治疗）。

二、教育及工作经历

1996年毕业于中山医科大学临床医学系，1999年获得中山大学肿瘤学硕士学位，1999年至今在中山大学肿瘤防治中心内科工作。2006年获得中山大学肿瘤学博士学位。2015-2016赴美国佛罗里达大学医学院进修。在肺癌治疗领域进行了深入的研究与探索。尤其对肺癌脑转移的临床和基础研究进行了多年的研究，包括药物在血脑屏障的通透性、化疗与脑放射联合治疗肺癌脑转移，肺癌脑转移的靶向治疗，肺癌脑转移的个体化治疗以及肺癌脑转移的机制研究，在相关领域取得较突出的研究和治疗成果。牵头国家自然科学及广东省自然科学基金项目，并与美国FSU医学院合作，开展多项针对肺癌脑转移的转化研究。在晚期肺癌的个体化治疗方面积累了独到的经验。负责及参加了多项肿瘤学省级及国家级研究项目。负责及参加多项国际及国内多中心肿瘤学新药临床研究项目。在国内外杂志发表相关论文60余篇。

三、学术兼职

广东省胸部肿瘤防治研究会脑转移专业委员会主任委员

中国抗癌协会神经肿瘤专业委员会脑转移瘤学组副组长

中国医药教育协会肿瘤转移专委会副主任委员

医师协会肿瘤内科医师分会副主任委员

广东省女子医师协会肺癌专业委员会副主任委员

中国抗癌协会抗癌药物专业委员会常委

中国药理学会肿瘤药理学专业委员会常委

广东省抗癌协会靶向治疗专业委员会常委

CSWOG肺癌专业委员会常委

广东省临床医学学会精准医疗专业委员会常委

广东省转化医学学会肿瘤学分会常委

四、主持科研项目

1. RNA甲基化调控VEGFA表达促肺癌脑转移的作用及机制研究

2. 国家自科科学基金委员会 2015 非小细胞肺癌脑转移特异性调控分子miR-143的作用及机制

3. 广东省自然科学基金管理委员会 2015 miR-27b促进非小细胞肺癌（NSCLC）脑转移的作用及分子机制

五、代表性论著

1. Xue Hou,Chengzhi Zhou,Guowu Wu,Wen Lin,Zhanhong Xie,Haibo Zhang,Jiqun Yi, Zheng Peng, Lifeng Yin,Chi Ma,Likun Chen, Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study, Journal of Thoracic Oncology.18(6):e769-779

2. Xue Hou; Meichen Li; Guowu Wu; Weineng Feng; Jin Su; Honghua Jiang; Guanming Jiang; Jing Chen; Baishen Zhang;Zhixuan You; Qing Liu; Likun Chen, Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study, JAMA Network Open. 2023;6(2):e2255050

3. Meichen Li, Jing Chen, Hui Yu, Baishen Zhang, Xue Hou, Honghua Jiang, Dan Xie, Likun Chen,Cerebrospinal fluid immunological cytokines predict intracranial tumor  response to immunotherapy in non-small cell lung cancer  patients with brain metastases, OncoImmunology , 2024, VOL. 13, NO. 1, 2290790

4. Meichen Li, Jing Chen, Baishen Zhang, Juan Yu, Na Wang, Delan Li, Yang Shao, Dongqin Zhu, Chuqiao Liang, Yutong Ma, Qiuxiang Ou, Xue Hou and Likun Chen, Dynamic monitoring of cerebrospinal fuid circulating tumor DNA to identify unique genetic profles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028), BMC Med. 2022 Nov 14;20(1):398

5. Xue Hou, Huamin Xu , Likun Chen, SRBD1-ALK, a Novel ALK Fusion Gene Identified in an Adenocarcinoma Patient by Next-Generation Sequencing, Journal of Thoracic Oncology, Apr 2019 14（4）：e72–e73

6. Hongsheng Wang, Qiuxiang Ou, Delan Li, Tao Qin, Hua Bao, Xue Hou, Kaicheng Wang, Fang Wang, Qianqian Deng, Jianzhong Liang, Wei Zheng, Xue Wu, Xiaonan Wang, Yang W. Shao, Yonggao Mou, MD and Likun Chen, MD, Genes Associated With Increased Brain Metastasis Risk in Non–Small Cell Lung Cancer: Comprehensive Genomic Profiling of 61 Resected Brain Metastases Versus Primary Non–Small Cell Lung Cancer (Guangdong Association Study of Thoracic Oncology 1036), Cancer Month 0, 2019

7. Xuewen Liu, Fang Wang, Chunwei Xu, Xin-ru Chen, Xue Hou, Qian Li, Pansong Li, Zhi Xie, Yongdong Liu, Lianpeng Chang, Yanfang Guan, Xuchao Zhang, Ling Yang, Hui Wang, Xin Yi, Jianjun Zhang, Xuefeng Xia, Moran Cesar, Likun Chen, Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma, Oncogene.2021 Jan;40(4):821-832

8. Meichen Li, Xue Hou, Ke Sai, Lihong Wu, Jing Chen, Baishen Zhang, Na Wang, Lijia Wu, Hongbo Zheng, Jiao Zhang, Yonggao Mou, Likun Chen, Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060), Oncoimmunology. 2022; VOL.11, NO.1, e2059874 (13 pages)

9. Meichen Li, Xue Hou, Lie Zheng, Yutong Ma, Delan Li, Yanchun Lv, Jing Chen, Wei Zheng, Yang Shao, Yonggao Mou, Likun Chen, Utilizing phenotypic characteristics of metastatic brain tumors to improvethe probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a prospective cohort study, ESMO Open. 2021 Dec 15;7(1):100305.

10. Meichen Li, Xue Hou, Jing Chen, Juan Yu, Meiting Chen, Na Wang, Baishen Zhang, Likun Chen, comparing organ-specific immune-related adverse events for immune checkpoint inhibitors:A bayesian network meta-analysis, Clin Transl Med.2021 Feb;11(2):e291

11. Meichen Li, Xue Hou, Jing Chen, Baishen Zhang, Na Wang, Hongyu Han, Likun Chen, ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061), Lung Cancer 165 (2022) 54–62

12. Xue Hou, Suxia Lin, Yongdong Liu, Kaicheng Wang, Zicheng Yu, Junhao Jia, Juan Yu, Wei Zheng, Jing Bai, Lianpeng Chang, Jing Chen, Meichen Li, Likun Chen, Analysis of the tumor microenvironment and mutation burden identifies prognostic features in thymic epithelial tumors, Am J Cancer Res 2022;12(5):2387-2396

13. shuang-Xin, wenfeng-Fang, jianwen-Li, delan-Li, changzheng-Wang, qanfei-Huang, ming-Huang, wei-Zhuang, xueding-Wang, likun-Chen, Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicty in ALK positive non-small cell lung cancer patients, J Cancer Res Clin Oncol.2021 Mar;147(3):725-737

14. Meichen Li, Xue Hou, Suxia Lin, Lie Zheng, Jianzhong Liang, Jing Chen, Na Wang, Baishen Zhang, Likun Chen, Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected EGFR-mutated non-small-cell lung cancer: a meta-analysis, Future Oncology.18(9):1159-1169

15. Xin-ru Chen, Xue Hou, De-lan Li, Ke Sai, Xiao-xiao Dinglin, Jing Chen, Na Wang, Mei-chen Li, Kai-cheng Wang, Li-kun Chen, Management of None Small-Cell Lung Cancer Patients Initially Diagnosed With 1 to 3 Synchronous Brain-Only Metastases: A Retrospective Study, Clin Lung Cancer.2021 Jan;22(1):e25-e34

16. Xiao-xiao Dinglin, Shu-xiang Ma, Fang Wang, De-lan Li, Jian-zhong Liang, Xin-ru Chen, Qing Liu, Yin-duo Zeng, Li-kun Chen, Establishment of an Adjusted Prognosis Analysis Model for Initially Diagnosed None Small-Cell Lung Cancer with Brain Metastases From Sun Yat-Sen University Cancer Center. Clinical Lung Cancer, 2017, Vol. 18, No. 3, e179-86

17. Meichen Li, Xue Hou, Chengzhi Zhou, Weineng Feng, Guanming Jiang, Hao Long, Shuang Yang, Jing Chen, Na Wang, Kaicheng Wang, Likun Chen, Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055), Front. Oncol.2020.10:1216

18. Xin-ru Chen, Xue Hou, De-lan Li, Ke Sai, Xiao-xiao Dinglin, Jing Chen, Na Wang, Mei-chen Li, Kai-cheng Wang, Li-kun Chen, Management of None Small-Cell Lung Cancer Patients Initially Diagnosed With 1 to 3 Synchronous Brain-Only Metastases: A Retrospective Study, Clin Lung Cancer. 2020 Jul 30; S1525-7304(20)30233-3

19. Xue-wen Liu, Xin-ru Chen, Yu-ming Rong, Ning Lyu, Chun-wei Xu, Fang Wang, Wen-yong Sun,San-gao Fang, Jing-ping Yuan, Hui-juan Wang, Wen-xian Wang, Wen-bin Huang, Jian-ping Xu,Zhen-ying Yue, Li-kun Chen, MET exon 14 skipping mutation, amplifification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study, Transl Oncol. 2020 Dec; 13(12): 100868

20. Xin-Ru Chen, Xue Hou, Xiao-Xiao Dinglin, Yong-Dong Liu, Yin Li, Wei Zheng, De-Lan Li, Jing Chen, Xiao-Liang Wu, Kai-Cheng Wang, Shu-Xiang Ma, Yin-Duo Zeng, Li-Kun Chen, Treatment Patterns and Survival Outcomes of Non-Small Cell Lung Cancer Patients Initially Diagnosed With Brain Metastases in Real-World Clinical Practice, Front Oncol. 2020 Oct 9;10:581729

21. Xinru Chen，Yu Zhang，Jiabin Lu，Chunwei Xu，Jiangzhong Liang，Fang Wang，Wenyong Sun，Sangao Fang，Jingping Yuan，Huijuan Wang，Hui Wang，Xuewen Liu，Likun Chen, Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor . Translational Oncology, April 2017, Vol. 10, No. 2, pp.115-120

六、获奖及荣誉

荣获2008赛克勒中国医师年度奖、2019广州实力中青年医生及2021羊城好医生

更新时间：2024.06.07